150 related articles for article (PubMed ID: 25707816)
1. Intra-abdominal temperature distribution during consolidation hyperthermic intraperitoneal chemotherapy with carboplatin in the treatment of advanced stage ovarian carcinoma.
Rettenmaier MA; Mendivil AA; Gray CM; Chapman AP; Stone MK; Tinnerman EJ; Goldstein BH
Int J Hyperthermia; 2015 Jun; 31(4):396-402. PubMed ID: 25707816
[TBL] [Abstract][Full Text] [Related]
2. Consolidation hyperthermic intraperitoneal chemotherapy for the treatment of advanced stage ovarian carcinoma: a 3 year experience.
Mendivil AA; Rettenmaier MA; Abaid LN; Brown JV; Mori KM; Lopez KL; Goldstein BH
Cancer Chemother Pharmacol; 2017 Aug; 80(2):405-410. PubMed ID: 28669065
[TBL] [Abstract][Full Text] [Related]
3. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial.
Deraco M; Kusamura S; Virzì S; Puccio F; Macrì A; Famulari C; Solazzo M; Bonomi S; Iusco DR; Baratti D
Gynecol Oncol; 2011 Aug; 122(2):215-20. PubMed ID: 21665254
[TBL] [Abstract][Full Text] [Related]
4. Abdomino-pelvic hyperthermia and intraperitoneal carboplatin in epithelial ovarian cancer: feasibility, tolerance and pharmacology.
Formenti SC; Shrivastava PN; Sapozink M; Jozsef G; Chan KK; Jeffers S; Morrow PC; Muggia FM
Int J Radiat Oncol Biol Phys; 1996 Jul; 35(5):993-1001. PubMed ID: 8751408
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial ovarian carcinoma: upfront therapy, at first recurrence, or later?
Gonzalez Bayon L; Steiner MA; Vasquez Jimenez W; Asencio JM; Alvarez de Sierra P; Atahualpa Arenas F; Rodriguez del Campo J; Garcia Sabrido JL
Eur J Surg Oncol; 2013 Oct; 39(10):1109-15. PubMed ID: 23870278
[TBL] [Abstract][Full Text] [Related]
6. Consolidation hyperthermic intraperitoneal chemotherapy and maintenance chemotherapy following laparoscopic cytoreductive surgery in the treatment of ovarian carcinoma.
Rettenmaier MA; Mendivil AA; Abaid LN; Brown Iii JV; Wilcox AM; Goldstein BH
Int J Hyperthermia; 2015 Feb; 31(1):8-14. PubMed ID: 25559985
[TBL] [Abstract][Full Text] [Related]
7. Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot study.
Argenta PA; Sueblinvong T; Geller MA; Jonson AL; Downs LS; Carson LF; Ivy JJ; Judson PL
Gynecol Oncol; 2013 Apr; 129(1):81-5. PubMed ID: 23352917
[TBL] [Abstract][Full Text] [Related]
8. The feasibility of administering varying high-dose consolidation hyperthermic intraperitoneal chemotherapy with carboplatin in the treatment of ovarian carcinoma.
Rettenmaier MA; Mendivil AA; Abaid LN; Brown JV; Micha JP; Wilcox AM; Goldstein BH
Arch Gynecol Obstet; 2015 Jun; 291(6):1381-6. PubMed ID: 25516177
[TBL] [Abstract][Full Text] [Related]
9. Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer.
Kim JH; Lee JM; Ryu KS; Lee YS; Park YG; Hur SY; Lee KH; Lee SH; Kim SJ
J Surg Oncol; 2010 Feb; 101(2):149-55. PubMed ID: 20035540
[TBL] [Abstract][Full Text] [Related]
10. Security and efficiency of a closed-system, turbulent-flow circuit for hyperthermic intraperitoneal chemotherapy after cytoreductive ovarian surgery: perioperative outputs.
Pascual-Ramírez J; Sánchez García S; González Ruiz de la Herrán F; Villarejo Campos P; López de la Manzanara Cano C; Haya Palazuelo J; Padilla Valverde D; Martín Fernández J
Arch Gynecol Obstet; 2014 Jul; 290(1):121-9. PubMed ID: 24488579
[TBL] [Abstract][Full Text] [Related]
11. Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer.
Gouy S; Ferron G; Glehen O; Bayar A; Marchal F; Pomel C; Quenet F; Bereder JM; Le Deley MC; Morice P
Gynecol Oncol; 2016 Aug; 142(2):237-42. PubMed ID: 27246305
[TBL] [Abstract][Full Text] [Related]
12. The role of cytoreductive surgery and HIPEC in epithelial ovarian cancer.
Halkia E; Spiliotis J
J BUON; 2015 May; 20 Suppl 1():S12-28. PubMed ID: 26051328
[TBL] [Abstract][Full Text] [Related]
13. A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer.
Chiva LM; Gonzalez-Martin A
Gynecol Oncol; 2015 Jan; 136(1):130-5. PubMed ID: 25434634
[TBL] [Abstract][Full Text] [Related]
14. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.
Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M
Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829
[TBL] [Abstract][Full Text] [Related]
15. Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: A pilot study of 31 patients.
Frenel JS; Leux C; Pouplin L; Ferron G; Berton Rigaud D; Bourbouloux E; Dravet F; Jaffre I; Classe JM
J Surg Oncol; 2011 Jan; 103(1):10-6. PubMed ID: 21031424
[TBL] [Abstract][Full Text] [Related]
16. Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study.
Pomel C; Ferron G; Lorimier G; Rey A; Lhomme C; Classe JM; Bereder JM; Quenet F; Meeus P; Marchal F; Morice P; Elias D
Eur J Surg Oncol; 2010 Jun; 36(6):589-93. PubMed ID: 20466507
[TBL] [Abstract][Full Text] [Related]
17. The Onset of Intra-Abdominal Adhesions During Closed-Abdomen Hyperthermic Intraperitoneal Chemotherapy.
Lotti M; Giulii Capponi M; Campanati L; Poiasina E; Ansaloni L; Poletti E; Frigerio L
J Laparoendosc Adv Surg Tech A; 2016 Dec; 26(12):997-1002. PubMed ID: 27705085
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal hyperthermic perfusion chemotherapy of patients with chemotherapy-resistant peritoneal disseminated ovarian cancer.
Hager ED; Dziambor H; Höhmann D; Mühe N; Strama H
Int J Gynecol Cancer; 2001; 11 Suppl 1():57-63. PubMed ID: 11489005
[TBL] [Abstract][Full Text] [Related]
19. Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series.
Fagotti A; Petrillo M; Costantini B; Fanfani F; Gallotta V; Chiantera V; Turco LC; Bottoni C; Scambia G
Gynecol Oncol; 2014 Feb; 132(2):303-6. PubMed ID: 24378877
[TBL] [Abstract][Full Text] [Related]
20. The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction.
Cascales-Campos PA; Gil J; Feliciangeli E; Gil E; González-Gil A; López V; Ruiz-Pardo J; Nieto A; Parrilla JJ; Parrilla P
Ann Surg Oncol; 2015 Mar; 22(3):987-93. PubMed ID: 25212832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
